

IHCP *bulletin*

INDIANA HEALTH COVERAGE PROGRAMS BT2023146 OCTOBER 31, 2023

Pharmacy updates approved by Drug Utilization Review Board October 2023

The Indiana Health Coverage Programs (IHCP) announces updates to SilentAuth automated prior authorization (PA) system, PA criteria, Over-the-Counter (OTC) Drug Formulary, and Statewide Uniform Preferred Drug List (SUPDL) as approved by the Drug Utilization Review (DUR) Board at its Oct. 20, 2023, meeting.

SilentAuth PA enhancement

The IHCP has enhanced its automated PA system to update the criteria for the Multiple Sclerosis Agents prior authorizations. These PA changes will be effective for PA requests submitted on or after Dec. 1, 2023. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* page on the Optum Rx Indiana Medicaid website, accessible from the [Pharmacy Services](#) page at in.gov/medicaid/providers.



PA changes

PA criteria for Non-SUPDL PA and Step Therapy and Skyclarys were established and approved by the DUR Board. PA changes for Non-SUPDL PA and Step Therapy and Skyclarys apply to the fee-for-service (FFS) benefit. These PA changes will be effective for PA requests submitted on or after Dec. 1, 2023. The PA criteria are posted on the *Pharmacy Prior Authorization Criteria and Forms* page on the [Optum Rx Indiana Medicaid website](#).

OTC Drug Formulary

Updates to the OTC Drug Formulary were established at the Oct. 20, 2023, DUR Board meeting. See Table 1 for the list of products included on the formulary. The formulary is effective for dates of service (DOS) on or after Dec. 1, 2023, unless otherwise noted.

Table 1 – OTC Drug Formulary effective for DOS on or after Dec. 1, 2023

Drug category	Drug	Status/Criteria
Agents for Opioid Overdose	Naloxone OTC nasal spray	Covered product
	Narcan OTC nasal spray	Covered product

Changes to the SUPDL

Changes to the SUPDL were made at the Oct. 20, 2023, DUR Board meeting. See Table 2 for a summary of SUPDL changes. Changes are effective for DOS on or after Dec. 1, 2023.

Table 2 – SUPDL changes effective for DOS on or after Dec. 1, 2023

Drug class	Drug	SUPDL status
Acne Agents	OTC Benzoyl peroxide cream, liquid, gel	Preferred
Agents for Opioid Use Disorder or Overdose	OTC Naloxone nasal spray	Preferred
	OTC Narcan nasal spray	Preferred
Topical Antifungals	OTC Terbinafine 1% cream	Preferred
	OTC Tolnaftate 1% cream, powder, spray	Preferred

For more information

The SUPDL, PA criteria, SilentAuth criteria, and OTC Drug Formulary can be found on the [Optum Rx Indiana Medicaid website](#). Notices of the DUR Board meetings and agendas are posted on the [FSSA website](#) at in.gov/fssa. Click **FSSA Calendar** on the left side of the page to access the events calendar.

Please direct FFS PA requests and questions about the SUPDL under the FFS pharmacy benefit or this bulletin to the Optum Rx Clinical and Technical Help Desk by calling toll-free 855-577-6317. Questions regarding pharmacy benefits for members in the Healthy Indiana Plan (HIP), Hoosier Care Connect and Hoosier Healthwise should be referred to the managed care entity (MCE) with which the member is enrolled.

COPIES OF THIS PUBLICATION

If you need additional copies of this publication, please download them from the [IHCP Bulletins](#) page of the IHCP provider website at in.gov/medicaid/providers.

SIGN UP FOR IHCP EMAIL NOTIFICATIONS

To receive email notices of IHCP publications, subscribe by clicking the blue subscription envelope or sign up from the [IHCP provider website](#) at in.gov/medicaid/providers.